DSM502 is a pyrrole-based Dihydroorotate Dehydrogenase (DHODH) inhibitor. DSM502 exhibits nanomolar potency againsts Plasmodium DHODH and Plasmodium parasites, with no inhibition of mammalian DHODHs.

DSM502 shows inhibitory activity against P. falciparum DHODH ( Pf DHODH, IC 50 =20 nM), P. vivax DHODH ( Pv DHODH, IC 50 =14 nM) and Pf 3D7 cells (EC 50 =14 nM), with no inhibition of the human enzyme[1].

DSM502 (10 and 50 mg/kg; p.o. once daily for 4 days) results in 97% parasite clearance in confirmatory SCID study compared to 85% clearance in the GSK study[1]. DSM502 (18.3 and 50 mg/kg; a single p.o.) exhibits high oral bioavailability (>100%, >100%), apparent t 1/2 (2.6, 3.6 h) and C max (8.4, 42.3 μM) in mice[1]. DSM502 (2.8 mg/kg; a single i.v.) exhibits apparent t 1/2 (2.8 h), plasma clearance (26.1 mL/min/kg), and V ss (1.2 L/kg) in mice[1]. Animal Model: SCID mice (23-36 g) were inoculated with parasites[1]Dosage: 10 and 50 mg/kg Administration: P.o. once daily for 4 days starting on day 3 after mice had been inoculated with parasites Result: Resulted in 97% parasite clearance compared to 85% clearance in the GSK study. The 10 mg/kg mouse died on day 5.

2426616-55-7

C16H16F3N3O

323.31

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years